Sight SciencesSGHT +1.74%72 Current Ratio is 5.86 as of Mar. 2026, which is 45% below its 10-year median of 10.74. GuruFocus rates SGHT with a GF Score™ of 72/100 and a GF Value™ of $4.49 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Sight Sciences ranks better than 83.02% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Sight Sciences's current ratio for the quarter that ended in Mar. 2026 was 5.86.
Sight Sciences has a current ratio of 5.86. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Sight Sciences's Current Ratio or its related term are showing as below:
SGHT'
s Current Ratio Range Over the Past 10 Years
Min: 2.47 Med: 10.74 Max: 27.9
Current: 5.86
During the past 8 years, Sight Sciences's highest Current Ratio was 27.90. The lowest was 2.47. And the median was 10.74.
SGHT's Current Ratio is ranked better than 83.02% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.485
vs SGHT: 5.86
Sight Sciences (NAS:SGHT) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Sight Sciences Current Ratio Related Terms
Sight Sciences Current Ratio Historical Data
* Premium members only.
The historical data trend for Sight Sciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sight Sciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sight Sciences Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Sight Sciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences (SGHT) has a Current Ratio of 5.86 as of Mar. 2026. This is 45% below median its historical median of 10.74. Over the past decade, Sight Sciences' Current Ratio has ranged from 2.47 to 27.90. According to the industry distribution chart, Sight Sciences ranks #145 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 17%.
Is Sight Sciences' Current Ratio too high?
Sight Sciences' current Current Ratio of 5.86 is 45% below median its 10-year median of 10.74. Over the past 10 years, this metric has ranged from a low of 2.47 to a high of 27.90. The Medical Devices & Instruments industry median Current Ratio is 2.49. Sight Sciences' value of 5.86 is 135.8% above this industry median. Based on the distribution chart, Sight Sciences ranks #145 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sight Sciences has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' Current Ratio compare to QSI and TMCI?
According to the Medical Devices & Instruments industry distribution chart, Sight Sciences ranks #145 out of 854 companies for Current Ratio. This places Sight Sciences in the top 17% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.49. Sight Sciences' value of 5.86 is 135.8% above this benchmark. Historically, Sight Sciences' own Current Ratio has ranged from 2.47 to 27.90 over the past decade. While the company's 10-year median is 10.74 vs. the industry median of 2.49, Sight Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sight Sciences's current Current Ratio of 5.86 is 135.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sight Sciences's current Current Ratio is 5.86, which is 45% below median its own 10-year median of 10.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.49, compared to a current price of $5.54 — trading 23.4% above its estimated fair value. The current Current Ratio is 5.86, which is 45% below median its 10-year median of 10.74 and 135.8% above the Medical Devices & Instruments industry median of 2.49. Sight Sciences' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Sight Sciences (SGHT), the current Current Ratio is 5.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sight Sciences (SGHT) Overvalued in 2026?
Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued.
The current stock price of $5.54 is trading 23.4% above its estimated GF Value™ of $4.49.
GuruFocus considers Sight Sciences to be Modestly Overvalued.
Key valuation signals for SGHT:
Current Ratio: 5.86 (45% below median its 10-year median of 10.74)
GF Value™: $4.49 vs. price of $5.54 (23.4% above fair value)
Industry Position: 135.8% above the Medical Devices & Instruments median (#145 of 854)
No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
72GF Score
Get the complete analysis for SGHT
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGHT has been successfully added to your 
